INO Inovio Pharmaceuticals Inc.

3.84
+0.4  (+12%)
Previous Close 3.44
Open 3.88
Price To Book 11.29
Market Cap 384,039,660
Shares 100,010,328
Volume 12,265,778
Short Ratio
Av. Daily Volume 1,199,912
Stock charts supplied by TradingView

NewsSee all news

  1. Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus

    PLYMOUTH MEETING, Pa., Jan. 23, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to

  2. Inovio Welcomes Biotech Leader to its Board of Directors

    PLYMOUTH MEETING, Pa., Jan. 15, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Jay Shepard to its Board of Directors. Mr. Shepard brings broad healthcare and financial

  3. BLS Pharma Alleges Inovio's Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender Community

    BLS Pharma, Inc. filed a complaint late last month against Genetronics, Inc. and Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Case No. 30-2019-01119045, for breaching a contract to supply a needle-free injection system

  4. Inovio Provides Update on Clinical Program Plans for 2020

    PLYMOUTH MEETING, Pa., Jan. 6, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that Inovio's President & CEO, Dr. J. Joseph Kim will present a corporate update of the company's

  5. Inovio Pharmaceuticals to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference

    PLYMOUTH MEETING, Pa., Nov. 25, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, will present in a fireside discussion at the Piper Jaffray 31st

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 overall survival data due 2020.
INO-5401 + cemiplimab
Glioblastoma (GBM)
Phase 1/2 trial discontinued - noted July 16, 2019.
INO-5401 and atezolizumab
Bladder cancer
Phase 1b data at ESMO 2018 noted 86% of patients remained progression-free after 72 weeks.
INO-5150
Prostate cancer
Phase 2 data due in 2020.
MEDI0457
HPV-associated squamous cell carcinoma of the head & neck (SCCHN)
Phase 2 data to be presented 1Q 2020.
VGX-3100
HPV-related pre-cancers - Vulvar Intraepithelial Neoplasia (VIN)
Phase 3 data due 4Q 2020.
VGX-3100 - REVEAL-1
Cervical dysplasia
Phase 2 data to be presented 1Q 2020.
VGX-3100
Human papilloma virus (HPV)-related anal dysplasia
Phase 2 interim data due 2020.
PENNVAX-GP
HIV
Phase 2 trial to be initiated in 2020.
INO-4700 / GLS-5300
MERS virus (Middle East Respiratory Syndrome)
Phase 2 commencement of dosing announced December 4, 2018.
MEDI0457
Human papilloma virus (HPV)
Phase 3 initiation announced March 4, 2019.
VGX-3100 - REVEAL-2
Cervical Dysplasia
Phase 1 data to be presented in 2020.
INO-4500
Lassa virus
Phase 1 trial announced July 29, 2019.
INO-5151
Castration-resistant Prostate Cancer
Phase 1 data due 2020.
INO-A002
Zika virus
Phase 2 trial to be initiated 1H 2020.
INO-3107
Recurrent respiratory papillomatosis

Latest News

  1. Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus

    PLYMOUTH MEETING, Pa., Jan. 23, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to

  2. Inovio Welcomes Biotech Leader to its Board of Directors

    PLYMOUTH MEETING, Pa., Jan. 15, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Jay Shepard to its Board of Directors. Mr. Shepard brings broad healthcare and financial

  3. BLS Pharma Alleges Inovio's Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender Community

    BLS Pharma, Inc. filed a complaint late last month against Genetronics, Inc. and Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Case No. 30-2019-01119045, for breaching a contract to supply a needle-free injection system

  4. Inovio Provides Update on Clinical Program Plans for 2020

    PLYMOUTH MEETING, Pa., Jan. 6, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that Inovio's President & CEO, Dr. J. Joseph Kim will present a corporate update of the company's

  5. Inovio Pharmaceuticals to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference

    PLYMOUTH MEETING, Pa., Nov. 25, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, will present in a fireside discussion at the Piper Jaffray 31st

  6. Inovio Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference

    PLYMOUTH MEETING, Pa., Nov. 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, will present in a fireside discussion at the Stifel 2019

  7. Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results

    PLYMOUTH MEETING, Pa., Nov. 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), an innovative biotechnology company focused on the discovery, development, and commercialization of synthetic DNA

  8. Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)

    80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months PLYMOUTH MEETING, Pa., Nov. 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today

  9. Inovio Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019

    PLYMOUTH MEETING, Pa., Oct. 29, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that third quarter 2019 financial results will be released after the market close on November 12, 2019.

  10. Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection

    PLYMOUTH MEETING, Pa., Sept. 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the company and its collaborator The Wistar Institute have received a $4.6 million National Institutes

  11. Inovio Pharmaceuticals to Present at Upcoming Investor Conferences

    PLYMOUTH MEETING, Pa., Sept. 3, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Joseph Kim, President and CEO, will present an Inovio overview and business update at two upcoming